SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Elan Corporation, plc (ELN)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Icebrg who wrote (1656)2/13/2002 5:12:50 PM
From: Qualified Opinion  Read Replies (1) of 10345
 
Excerpt from your post "Moody's expects that Elan's 2002 cash flow will be impacted by higher R&D to support clinical trials and larger SG&A expenses for salesforce expansion. Furthermore, Moody's anticipates 2002 capital expenditures in the range of $200 to $250 million in part to increase manufacturing capacity and to establish biologics capabilities. Based on this information, Moody's stated that its review of Elan's cash flow relative to debt levels (both gross debt and net debt) is a factor"

Elan is growing.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News